The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.
Paul Eliezer Oberstein
No relevant relationships to disclose
Anthony Paul Gulati
No relevant relationships to disclose
Benjamin A Krantz
No relevant relationships to disclose
Rebecca Anne Moss
No relevant relationships to disclose
Stephen M. Schreibman
No relevant relationships to disclose
Dawn Tsushima
No relevant relationships to disclose
Kelley B Mowatt
No relevant relationships to disclose
John Allendorf
No relevant relationships to disclose
Beth Schrope
No relevant relationships to disclose
James A Lee
No relevant relationships to disclose
William H. Sherman
No relevant relationships to disclose
John A Chabot
No relevant relationships to disclose
Robert Fine
No relevant relationships to disclose